Radiopharm Theranostics Ltd (ASX:RAD) managing director and CEO Riccardo Canevari chats with Andrew Scott from Proactive about the important joint venture with MD Anderson. Canevari discusses the Phase 2a study in brain metastasis, overall clinical development and focus on Australia.
Radiopharm Theranostics to accelerate development of Pivalate platform technology
